Mahesh, I have no gripe. My job is to report and initiate or contribute to public discourses. To your point on the market share, which a few other readers have incorrectly raised too, Indian vaccine makers don't have a signifiant market share. The global vaccine market in 2020 is about $35-38 billion. Indian vaccine makers, if you add their total vaccine earnings, together gross less than $1.5B in annual revenue. So that's nowhere close to any significant market share. As I have said before, none of these companies sell in any regulated market, most supply to governments or Aid agencies.
It's not about aping the rich countries at all. It's about building your base. Think about it- other than Zydus no one has a vaccine candidate of their. It's all US collaboration. Why?
As for finding funds, not sure how much VC investment in life "sciences" you follow in India. There's no risk capital available because there's no e-comm or edtech like exit in this sector. It's a slow burn, long gestation sector. There's been a dearth of great startups, but there's been a greater dearth of risk capital for life sciences. I've followed this sector for very long and hence say this with some conviction. Plus, vaccine manufacturing is complex (not like generics).